Merck & Co. Inc.’s patent infringement suit against Mylan Pharmaceuticals, Inc. relating to ezetimibe/simvastatin is pending.
In November 2009, Schering Corp. received notice from Mylan that it filed an ANDA for…
Merck & Co. Inc. continues to pursue patent infringement suits in federal court against companies filing ANDA’s for generic montelukast (Singulair), aprepitant (Emend) and caspofungin (Cancidas). AstraZeneca and the Company…
Merck & Co. Inc. and Glenmark Pharmaceuticals, Inc. USA and its parent corporation reached a settlement of a patent infringement lawsuit relating to Zetia in May 2010.
In February 2007, Schering-Plough…
Merck & Co., Inc.’s patent infringement suit against Glenmark Pharmaceuticals Inc., USA is scheduled to go to trial on May 3, 2010.
In February 2007, Schering-Plough received a notice from a…
The decision invalidating Merck & Co. Inc.’s Japanese patent for the once-weekly administration of alendronate remains under appeal.
In Japan, after a proceeding was filed challenging the validity of the Company’s…
MSD continues to pursue patent infringement suits in federal court against companies filing ANDA’s for generic alendronate (Fosamax) and montelukast (Singulair). AstraZeneca and MSD have filed patent infringement suits in…
Merck & Co. Inc. and E.I. du Pont de Nemours are pursuing patent infringement proceedings against various companies in Portugal, Spain, Norway and Austria.
In Europe, the Company is aware of…
Merck & Co. Inc. continues to pursue a patent infringement lawsuit against Sandoz Inc.
The Company and AstraZeneca received notice in December 2008, that Sandoz had filed an abbreviated new drug…
Merck & Co., Inc. disclosed that in January 2010, the Supreme Court of Canada declined to hear the Company’s appeal to a decision on Apotex Corp.’s alendronate patent proceeding.
In May…
Merck & Co. Inc. is involved in litigation proceedings of patent for dorzolamide in Canada and Great Britain and Germany.
In October 2008, the U.S. patent for dorzolamide, covering both Trusopt…